EGFR and colorectal carcinoma: The authors analyzed the response of 7 CRC cell lines to cetuximab as well as primary tumors, liver and lung metastasis from 25 CRC patients treated with cetuximab or panitumumab, by evaluating NGS (Illumina) mutation profiles of 48 cancer-related genes, EGFR and E-cadherin expression.